Skip to content
AnalystLens

CVS HEALTH Corp 8-K Report, Corporate Update (Dec 9, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed December 9, 2024
Period End
December 9, 2024
Security
CVS
In the record · 2016–202610-K1110-Q328-K181

CVS filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 181 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Nov ’18Nov ’18
  2. Leadership change8-K · Sep ’22Sep ’22
  3. Leadership change8-K · Aug ’26Aug ’26

01—Abstract

Summary

Summary of the 8-K filed December 9, 2024. Cited figures are marked; the original filing is the authoritative source.

CVS Health Corporation announced on December 9, 2024 the expiration and preliminary results of its cash tender offers, specifically the 'Any and All' tender offer for its 4.100%a Senior Notes due 2025.

As of the 5:00 p.m. NYC time expiration on December 6, 2024, holders validly tendered $225,979,000b in principal amount of the $950,087,000 outstanding notes, with an additional $5,000 tendered via guaranteed delivery procedures. CVS expects to accept all validly tendered notes, with settlement expected on December 11, 2024.

The filing indicates the transaction is a liability management action, with the purchases to be funded partly from proceeds of newly issued 7.000% Series A Junior Subordinated Notes due 2055 and 6.750% Series B Junior Subordinated Notes due 2054. The filing also references a concurrent Maximum Tender Offer capped at $2.0 billionc less the aggregate purchase price of Any and All Notes accepted, meaning the size of that second offer is contingent on the Any and All results and may change as guaranteed-delivery notes settle. The 8-K itself is a routine disclosure under Item 8.01 with the press release furnished as Exhibit 99.1; it does not disclose new earnings, guidance, or operating results.

The press release includes a boilerplate note that no recommendation is made to holders regarding tendering. For investors, the key takeaways are the refinancing nature of the transaction, which replaces near-term 2025 maturities with longer-dated junior subordinated debt carrying higher coupons, and the modest scale of the Any and All tender relative to CVS's overall debt structure. Investors should review the Offer to Purchase and the terms of the New Notes for the full economic impact on interest expense and leverage.

02—Key points

Key Highlights

  1. Any and All tender offer for 4.100% Senior Notes due 2025: $225,979,000 validly tendered out of $950,087,000 outstanding (about 23.8%), plus $5,000 via guaranteed delivery.
  2. CVS expects to accept all validly tendered Any and All Notes; settlement expected December 11, 2024.
  3. Funding comes partly from new 7.000% Series A Junior Subordinated Notes due 2055 and 6.750% Series B Junior Subordinated Notes due 2054, indicating a refinancing of 2025 maturities with longer-dated junior subordinated debt.
  4. A concurrent Maximum Tender Offer is capped at $2.0 billion less the Any and All purchase price, so its final size remains subject to change.
  5. Guaranteed delivery deadline for remaining Any and All Notes is 5:00 p.m. NYC time on December 10, 2024, unless extended.
  6. The filing is a routine Item 8.01 disclosure with the press release furnished as Exhibit 99.1; it contains no new earnings, guidance, or operating results.
  7. Tender offer dealer managers are Barclays Capital Inc. and Mizuho Securities USA LLC; D.F. King & Co. is the tender and information agent.

03—Questions

Frequently Asked Questions

  1. What did CVS Health announce in this 8-K filing?

    CVS announced the expiration and results of its cash tender offer for any and all of its 4.100% Senior Notes due 2025, as well as the status of a related Maximum Tender Offer. The announcement was made via press release dated December 9, 2024, attached as Exhibit 99.1.

  2. How much of the 2025 notes were tendered?

    Holders validly tendered $225,979,000 in principal amount of the $950,087,000 outstanding 4.100% Senior Notes due 2025 by the December 6, 2024 expiration, and an additional $5,000 was tendered under guaranteed delivery procedures. This represents roughly 24% of the outstanding notes.

  3. How is CVS funding the tender offer purchases?

    CVS said it will fund part of the purchases with proceeds from newly issued 7.000% Series A Junior Subordinated Notes due 2055 and 6.750% Series B Junior Subordinated Notes due 2054. The filing does not state the exact amount raised or the total funding needed.

  4. When will the purchases settle and what could still change?

    Settlement is expected on December 11, 2024, the third business day after expiration. The Maximum Tender Offer amount may change because the guaranteed delivery notes remain outstanding and because the cap is reduced by the Any and All purchase price, so final amounts are not yet fixed.

  5. Does this filing change CVS's financial outlook?

    The filing itself contains no new earnings, guidance, or operating results. It is a debt management transaction, so its investor impact depends on the cost of the new junior subordinated notes versus the retired 2025 notes and on the scale of the overall program described in the Offer to Purchase.

04—Continue

← View all 8-K filings